Screener
Tango Therapeutics TNGX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation | 463 | 622 |
| Noncash operating lease expense | 972 | 1,012 |
| Stock-based compensation | 10,797 | 7,255 |
| Accretion on marketable securities | (1,124) | (638) |
| Other, net | 21 | (56) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,299) | 649 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's stock-based comp?
- Tango Therapeutics (TNGX) reported stock-based comp of $10.8M in Q1 2026.
- How has Tango Therapeutics's stock-based comp changed year-over-year?
- Tango Therapeutics's stock-based comp increased by 48.8% year-over-year, from $7.26M to $10.8M.
- What is the long-term trend for Tango Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Tango Therapeutics's stock-based comp has grown at a 35.5% compound annual growth rate (CAGR), from $7.83M to $26.43M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Tango Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude